Thomas R. Barber

Treatment Selection and Prioritization for the EJS ACT ‐ PD MAMS Trial Platform

Cristina Gonzalez‐Robles, Dilan Athauda, Thomas R. Barber, Roger A. Barker et autres

BACKGROUND: There are currently no disease-modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT-PD) initiative will expedite clinical assessment of putative DMTs through a multi-arm multistage (MAMS) trial, testing several treatments …

gb (code pays fourni par la source)

Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease

Shijun Yan, Cheng Jiang, Annette Janzen, Thomas R. Barber et autres

IMPORTANCE: Nonmotor symptoms of Parkinson disease (PD) often predate the movement disorder by decades. Currently, there is no blood biomarker to define this prodromal phase. OBJECTIVE: To investigate whether α-synuclein in neuronally derived serum-extracellular vesicles identifies individuals at risk of developing PD …

gb, de, us (code pays fourni par la source)

Reward insensitivity is associated with dopaminergic deficit in rapid eye movement sleep behaviour disorder

Thomas R. Barber, Kinan Muhammed, Daniel Drew, Kevin M. Bradley et autres

Idiopathic rapid eye movement sleep behaviour disorder (iRBD) has now been established as an important marker of the prodromal stage of Parkinson's disease and related synucleinopathies. However, although dopamine transporter single photon emission computed tomography (SPECT) has been used to demonstrate the …

gb (code pays fourni par la source)

Mouse fetal growth restriction through parental and fetal immune gene variation and intercellular communications cascade

Gurman Kaur, Caroline Porter, Orr Ashenberg, Samantha J. Riesenfeld et autres

Fetal growth restriction (FGR) affects 5-10% of pregnancies, and can have serious consequences for both mother and child. Prevention and treatment are limited because FGR pathogenesis is poorly understood. Genetic studies implicate KIR and HLA genes in FGR, however, linkage disequilibrium, genetic …

us, gb, de, dk (code pays fourni par la source)

Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts

Michael Lawton, Manuela Tan, Yoav Ben‐Shlomo, Fahd Baig et autres

OBJECTIVES: To explore the genetics of four Parkinson's disease (PD) subtypes that have been previously described in two large cohorts of patients with recently diagnosed PD. These subtypes came from a data-driven cluster analysis of phenotypic variables. METHODS: We looked at the …

gb (code pays fourni par la source)

A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson’s disease

Christine Lo, Siddharth Arora, Michael Lawton, Thomas R. Barber et autres

BACKGROUND: An unmet need remains for sensitive outcome measures in neuroprotective trials. The study aims to determine whether a composite clinical motor score, combining the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III motor examination score, Purdue Pegboard Test, and Timed …

gb, us, ca (code pays fourni par la source)

Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study

Yaping Liu, Michael Lawton, Christine Lo, Francesca Bowring et autres

BACKGROUND: Parkinson's disease (PD) comorbid with rapid eye movement sleep behavior disorder (RBD) may show more severe motor and nonmotor symptoms, suggesting a distinct PD subtype. OBJECTIVE: The aim of this study was to investigate the impact of RBD on the longitudinal …

hk, gb, es (code pays fourni par la source)

Parental-fetal interplay of immune genes leads to intrauterine growth restriction

Gurman Kaur, Caroline Porter, Orr Ashenberg, Jack Lee et autres

Abstract Intrauterine growth restriction (IUGR) of fetuses affects 5-10% of pregnancies and is associated with perinatal morbidity, mortality and long-term health issues. Understanding genetic predisposition to IUGR is challenging, owing to extensive gene polymorphisms, linkage disequilibrium, and maternal and paternal influence. Here, …

us, gb, de, dk (code pays fourni par la source)

Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder

Dario Arnaldi, A. Chincarini, Karel Šonka, Bradley F. Boeve et autres

This is an international multicentre study aimed at evaluating the combined value of dopaminergic neuroimaging and clinical features in predicting future phenoconversion of idiopathic REM sleep behaviour (iRBD) subjects to overt synucleinopathy. Nine centres sent 123I-FP-CIT-SPECT data of 344 iRBD patients and …

it, gb, cz, us, jp, fr (code pays fourni par la source)

Cohort profile: the Oxford Parkinson’s Disease Centre Discovery Cohort MRI substudy (OPDC-MRI)

Ludovica Griffanti, Johannes Klein, Konrad Szewczyk‐Królikowski, Ricarda Menke et autres

PURPOSE: The Oxford Parkinson's Disease Centre (OPDC) Discovery Cohort MRI substudy (OPDC-MRI) collects high-quality multimodal brain MRI together with deep longitudinal clinical phenotyping in patients with Parkinson's, at-risk individuals and healthy elderly participants. The primary aim is to detect pathological changes in …

gb (code pays fourni par la source)

Clinical and neuroimaging markers of prodromal neurodegeneration in rapid eye movement sleep behaviour disorder

Thomas R. Barber

Patients with rapid eye movement sleep behaviour disorder (RBD) have a high long-term risk of developing Parkinson’s disease or a related synucleinopathy. Their individual trajectories are enormously varied, however, causing considerable prognostic uncertainty. This thesis examined aspects of the clinical and neuroimaging …

Nigrosome 1 imaging in REM sleep behavior disorder and its association with dopaminergic decline

Thomas R. Barber, Ludovica Griffanti, Kevin M. Bradley, Daniel R. McGowan et autres

Abstract Objectives Rapid eye movement sleep behavior disorder (RBD) patients have a high risk of developing a Parkinsonian disorder, offering an opportunity for neuroprotective intervention. Predicting near‐term conversion, however, remains a challenge. Dopamine transporter imaging, while informative, is expensive and not widely …

gb (code pays fourni par la source)